CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

• Claire M. Lucas,
• Laura J. Scott,
• Natasha Carmell,
• Alison K. Holcroft,
• Robert K. Hills,
• Alan K. Burnett,
• Richard E. Clark

Affiliations

Claire M. Lucas

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;; Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom;; Claire M. Lucas, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Sherrington Building, Ashton St, Liverpool L69 3GE, United Kingdom;

Laura J. Scott

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;

Natasha Carmell

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;

Alison K. Holcroft

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;

Robert K. Hills

Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom

Alan K. Burnett

Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom

Richard E. Clark

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;; Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom;